PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
253.38%
Net income growth under 50% of VET's 1204.66%. Michael Burry would suspect deeper structural issues in generating bottom-line growth.
1.63%
Some D&A expansion while VET is negative at -9.02%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
-50.59%
Negative yoy deferred tax while VET stands at 161.87%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
-48.89%
Both cut yoy SBC, with VET at -3.85%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
-73.91%
Negative yoy working capital usage while VET is 124.20%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
202.94%
AR growth of 202.94% while VET is zero at 0.00%. Bruce Berkowitz would see a mild difference in credit approach that could matter for cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-150.00%
Negative yoy usage while VET is 124.20%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
-97.87%
Both negative yoy, with VET at -221.93%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
-46.73%
Negative yoy CFO while VET is 7.71%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
-13.03%
Negative yoy CapEx while VET is 32.34%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
-637.50%
Negative yoy acquisition while VET stands at 100.00%. Joel Greenblatt sees potential short-term cash advantage unless competitor’s deals yield big synergy.
714.29%
Purchases growth of 714.29% while VET is zero at 0.00%. Bruce Berkowitz sees a mild difference in portfolio building that might matter for returns.
-84.42%
We reduce yoy sales while VET is 0.00%. Joel Greenblatt sees competitor possibly capitalizing on market peaks or forced to raise cash while we hold tight.
-32.12%
We reduce yoy other investing while VET is 19.36%. Joel Greenblatt sees a near-term cash advantage unless competitor’s intangible or side bets produce strong returns.
-57.96%
We reduce yoy invests while VET stands at 34.57%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
5.88%
Debt repayment above 1.5x VET's 2.69%, indicating stronger deleveraging. David Dodd would verify if expansions are not neglected.
-100.00%
Negative yoy issuance while VET is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.